|  | | 5752 | Abatacept(Orencia®)forInjectionforIntravenousUse08.00.62o | Pharmacy (08) | 08.00.62o | 08.00.62 | d5348acb-dad2-4abe-aba8-f51b4839d7b7 | Abatacept (Orencia®) for Injection for Intravenous Use | Abatacept (Orencia®) for Injection for Intravenous Use | {"5753": {"Id":5753,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":7706,"PolicyAttachmentPageName":"62ae2f55-b985-4947-ad5c-4a67fd399e25"},} |
| | | 5669 | Acupuncture12.00.01h | Miscellaneous (12) | 12.00.01h | 12.00.01 | 77df5bd1-45ad-4977-b7aa-e48b58521792 | Acupuncture | Acupuncture | {"5670": {"Id":5670,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":7649,"PolicyAttachmentPageName":"5f5f97d7-b563-4acc-90b4-e681bdbd4c17"},} |
| | | 5536 | AcuteCareFacilityInpatientTransfers12.04.04b | Miscellaneous (12) | 12.04.04b | 12.04.04 | 1cfcdcfa-8618-4278-b580-4cb85d35ce0c | Acute Care Facility Inpatient Transfers | Acute Care Facility Inpatient Transfers | |
| | | 4949 | Ado-TrastuzumabEmtansine(Kadcyla®)08.01.11h | Pharmacy (08) | 08.01.11h | 08.01.11 | 38d8a45c-488c-48e3-988a-04ec71fc747f | Ado-Trastuzumab Emtansine (Kadcyla®) | Ado-Trastuzumab Emtansine (Kadcyla®) | {"4950": {"Id":4950,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":6792,"PolicyAttachmentPageName":"22019f47-888f-4ab7-b554-9fe0c2c91809"},} |
| | | 5163 | Agalsidasebeta(Fabrazyme®)08.00.69c | Pharmacy (08) | 08.00.69c | 08.00.69 | b8b27d69-62ab-4921-9ae8-f074ee40c9dc | Agalsidase beta (Fabrazyme®) | Agalsidase beta (Fabrazyme®) | |
| | | 5440 | AirAmbulanceServices12.04.03c | Miscellaneous (12) | 12.04.03c | 12.04.03 | 54421f21-0a89-4d2b-b568-b43c51393668 | Air Ambulance Services | Air Ambulance Services | |
| | | 5305 | Alemtuzumab(Lemtrada®)08.01.22d | Pharmacy (08) | 08.01.22d | 08.01.22 | 253c8671-81ff-425d-9d8e-309011c90aa0 | Alemtuzumab (Lemtrada®) | Alemtuzumab (Lemtrada®) | |
| | | 5359 | Alglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®)08.00.72k | Pharmacy (08) | 08.00.72k | 08.00.72 | 8efb377e-0527-4def-a962-5f79e0b36912 | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ) | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ) | |
| | | 4820 | AllergyImmunotherapy07.00.21j | Medicine (07) | 07.00.21j | 07.00.21 | a1de565a-4780-477e-8f16-1cbce906084c | Allergy Immunotherapy | Allergy Immunotherapy | |
| | | 5178 | AllogeneicProcessedThymusTissue-agdc(Rethymic®)08.01.88 | Pharmacy (08) | 08.01.88 | 08.01.88 | b94000e7-dd84-4ae8-b8f9-3712a52d80da | Allogeneic Processed Thymus Tissue-agdc (Rethymic®) | Allogeneic Processed Thymus Tissue-agdc (Rethymic®) | |
| | | 5224 | AlloMap™MolecularExpressionTestingforHeartTransplantRejection(AmeriHealthAdministrators)06.02.29d | Pathology and Laboratory (06) | 06.02.29d | 06.02.29 | 79251573-4f96-4f72-96e8-6488e1cc8797 | AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (AmeriHealth Administrators) | AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (AmeriHealth Administrators) | |
| | | 5230 | Alpha1-AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91e | Pharmacy (08) | 08.00.91e | 08.00.91 | 89deaeea-96aa-4381-9a71-4bc587fb08c9 | Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) | Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) | |
| | | 5524 | AlwaysBundledProcedureCodes00.01.52s | Administrative (00) | 00.01.52s | 00.01.52 | 4dbd90d3-e8eb-4791-8ebf-3170964d453f | Always Bundled Procedure Codes | Always Bundled Procedure Codes | {"5525": {"Id":5525,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":7487,"PolicyAttachmentPageName":"fbf1857d-c74e-4410-9556-1faa34bb798c"},"5526": {"Id":5526,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (Indicator B)","MPPolicyAttachmentInternalSourceId":7488,"PolicyAttachmentPageName":"76f09a54-7327-4e5a-9dda-5905ab41a475"},"5527": {"Id":5527,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":7489,"PolicyAttachmentPageName":"bc10af0c-b796-4883-9ed5-62ebb608a4d8"},} |
| | | 5674 | AmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09i | Medicine (07) | 07.02.09i | 07.02.09 | 60934549-b89d-4621-9139-ae8356ccea80 | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | |
| | | 5682 | AmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21m | Medicine (07) | 07.02.21m | 07.02.21 | 9ce53a68-591b-4581-9875-fd5cbd286ed7 | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | |
| | | 5678 | AnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagement01.00.12b | Anesthesia (01) | 01.00.12b | 01.00.12 | 2d5afb71-f0c1-41d0-9ac2-8547f69eeced | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | {"5679": {"Id":5679,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7647,"PolicyAttachmentPageName":"20157e6f-30d2-4d70-bade-2b66b07e647f"},} |
| | | 5431 | Anifrolumab-fnia(Saphnelo®)08.01.82b | Pharmacy (08) | 08.01.82b | 08.01.82 | 7f881bbb-9ecf-4690-b6b8-6f5cb234c8f7 | Anifrolumab-fnia (Saphnelo®) | Anifrolumab-fnia (Saphnelo®) | |
| | | 5159 | Ankle-Foot/Knee-Ankle-FootOrthoses05.00.39s | DME (05) | 05.00.39s | 05.00.39 | 9fe524ee-227c-45ca-894a-d481fa0fef99 | Ankle-Foot/Knee-Ankle-Foot Orthoses | Ankle-Foot/Knee-Ankle-Foot Orthoses | {"5160": {"Id":5160,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":7044,"PolicyAttachmentPageName":"7d58f450-832e-4572-9279-da5bf832159f"},} |
| | | 2807 | ApheresisTherapy06.03.04n | Pathology and Laboratory (06) | 06.03.04n | 06.03.04 | b395fd09-303a-4b18-a74c-04bb56dc9226 | Apheresis Therapy | Apheresis Therapy | |
| | | 5107 | ApplicationandRemovalofTattoos11.08.05g | Surgery (11) | 11.08.05g | 11.08.05 | 40adc8e6-69c1-4b04-9492-4dde285906f2 | Application and Removal of Tattoos | Application and Removal of Tattoos | |
| | | 5039 | AppliedBehaviorAnalysis(ABA)fortheTreatmentofAutismSpectrumDisorders(ASD)14.00.03 | Behavioral Health (14) | 14.00.03 | 14.00.03 | 5ab4e14d-6b67-4846-85eb-07d9a15c7819 | Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD) | Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD) | |
| | | 4993 | Aprepitant(Cinvanti™),FosaprepitantDimeglumine(Emend®),Granisetron(Sustol®),andRolapitant(Varubi®)08.01.41e | Pharmacy (08) | 08.01.41e | 08.01.41 | b59e539f-57fe-4c9e-97c1-f32cbacecfd4 | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | {"4994": {"Id":4994,"MPAttachmentLetter":"A","Title":"Risk of Emesis Without Prophylaxis: Intravenous and Oral Antineoplastic Agents","MPPolicyAttachmentInternalSourceId":7122,"PolicyAttachmentPageName":"3ba22a0e-77fb-40a0-b6ac-db0a5f7a1f4d"},} |
| | | 4998 | AqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16l | Surgery (11) | 11.05.16l | 11.05.16 | b55c31d5-eb8d-4517-bf3c-eeeb6c9b79a1 | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | {"4999": {"Id":4999,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":7061,"PolicyAttachmentPageName":"fdf22af8-1f6d-44a3-bf8f-874a014f596a"},} |
| | | 5311 | ArtificialIntervertebralCervicalDiscInsertion(AmerihealthAdministrators)11.14.19p | Surgery (11) | 11.14.19p | 11.14.19 | bc52c9e0-2f80-4074-92f6-4627d2247b46 | Artificial Intervertebral Cervical Disc Insertion (Amerihealth Administrators) | Artificial Intervertebral Cervical Disc Insertion (Amerihealth Administrators) | |
| | | 4989 | ArtificialIntervertebralLumbarDiscInsertion11.15.31b | Surgery (11) | 11.15.31b | 11.15.31 | afb41ec7-458d-467b-b4e7-e59d90e2de3d | Artificial Intervertebral Lumbar Disc Insertion | Artificial Intervertebral Lumbar Disc Insertion | |
| | | 5453 | AsparaginaseErwiniaChrysanthemi(Erwinaze®),asparaginaseerwiniachrysanthemi(recombinant)-rywn(Rylaze®)08.01.35g | Pharmacy (08) | 08.01.35g | 08.01.35 | 45eea1e5-d113-4c3c-a874-49b1e3d094b0 | Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®) | Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®) | |
| | | 5557 | AssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(AmeriHealthAdministrators)06.02.27n | Pathology and Laboratory (06) | 06.02.27n | 06.02.27 | 9df36788-e9f1-4d47-a9c2-21f112f4b6b4 | Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (AmeriHealth Administrators) | Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (AmeriHealth Administrators) | |
| | | 4861 | AssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06i | Medicine (07) | 07.10.06i | 07.10.06 | 1957f95b-a5e6-40c1-befd-604f31a47e21 | Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation | Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation | |
| | | 5120 | Atezolizumab(Tecentriq®)08.01.69c | Pharmacy (08) | 08.01.69c | 08.01.69 | 3692eb86-55ea-4cdd-a607-efd8374b8545 | Atezolizumab (Tecentriq®) | Atezolizumab (Tecentriq®) | {"5121": {"Id":5121,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7179,"PolicyAttachmentPageName":"d42f2057-342f-4f9c-848b-430f95990f97"},} |
| | | 5239 | AutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(AmerihealthAdministrators)11.14.06j | Surgery (11) | 11.14.06j | 11.14.06 | 2128d5d8-b7a4-4ff5-9a1a-9608698cc0eb | Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Amerihealth Administrators) | Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Amerihealth Administrators) | |
| | | 5683 | AutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29o | DME (05) | 05.00.29o | 05.00.29 | a590a8dc-f63a-4148-bbaf-c1db550f4901 | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | {"5684": {"Id":5684,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":7702,"PolicyAttachmentPageName":"72e465f4-a6d8-47da-947d-a60610ca93bc"},"5685": {"Id":5685,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":7703,"PolicyAttachmentPageName":"2d28e7c9-989c-4508-ad0f-ead9d9e10f0a"},} |
| | | 5340 | AutonomicNervousSystemTesting07.03.23f | Medicine (07) | 07.03.23f | 07.03.23 | b393d397-a419-44af-9b52-d0c610c1ee8c | Autonomic Nervous System Testing | Autonomic Nervous System Testing | |
| | | 4958 | Avelumab(Bavencio®)08.01.64b | Pharmacy (08) | 08.01.64b | 08.01.64 | f20a2a02-1ded-4005-9bf4-693e1c2fd092 | Avelumab (Bavencio®) | Avelumab (Bavencio®) | {"4959": {"Id":4959,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7008,"PolicyAttachmentPageName":"f9d6f03c-2dca-4ee9-b5d8-afcceee6e029"},} |
| | | 5096 | BalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitis11.16.06j | Surgery (11) | 11.16.06j | 11.16.06 | e6e1f2fb-cb7d-4b62-b88c-93f6f4dbaaa6 | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | |
| | | 2824 | BariatricSurgery11.03.02t | Surgery (11) | 11.03.02t | 11.03.02 | deb6788b-9378-4634-bea1-f71971bb7026 | Bariatric Surgery | Bariatric Surgery | {"2825": {"Id":2825,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":4907,"PolicyAttachmentPageName":"1ae6209c-f0da-459c-adb3-cace9e40b535"},"2826": {"Id":2826,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":4908,"PolicyAttachmentPageName":"3fc8cbfa-375e-4a3f-a769-c3bd36fe1065"},"2827": {"Id":2827,"MPAttachmentLetter":"C","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":4909,"PolicyAttachmentPageName":"778a747c-2dd7-41ec-a720-71eec3fa4351"},} |
| | | 5303 | Belimumab(Benlysta®)forIntravenousUse08.00.99e | Pharmacy (08) | 08.00.99e | 08.00.99 | 48faca03-d3ad-4abd-af51-f1fdd06652c8 | Belimumab (Benlysta®) for Intravenous Use | Belimumab (Benlysta®) for Intravenous Use | |
| | | 5611 | BeremageneGeperpavec(Vyjuvek™)08.02.10 | Pharmacy (08) | 08.02.10 | 08.02.10 | 87c3f070-2bb4-4558-8c27-bb164294d05a | Beremagene Geperpavec (Vyjuvek™) | Beremagene Geperpavec (Vyjuvek™) | |
| | | 4970 | BetibeglogeneAutotemcel[Beti-Cel(ZYNTEGLO®)]08.01.89 | Pharmacy (08) | 08.01.89 | 08.01.89 | f4038900-116f-45a9-a1d0-49644aa0544d | Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)] | Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)] | |
| | | 5394 | Bevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66u | Pharmacy (08) | 08.00.66u | 08.00.66 | 5e39b1ae-f374-4b43-a5f0-9444ff939207 | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | {"5395": {"Id":5395,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":7256,"PolicyAttachmentPageName":"ae2016c2-03bb-4ed9-986e-15e23b1bcb87"},"5396": {"Id":5396,"MPAttachmentLetter":"B","Title":"ICD 10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":7322,"PolicyAttachmentPageName":"c3be9297-30ef-4a4c-a768-0bcb23746e8f"},} |
| | | 5080 | BillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39p | Administrative (00) | 00.10.39p | 00.10.39 | 974307f4-0c12-4fca-a95c-49747a501e32 | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | {"5081": {"Id":5081,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":7191,"PolicyAttachmentPageName":"381f14d3-4b02-400b-92cd-7ab75b59686a"},} |
| | | 3087 | BillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38a | Administrative (00) | 00.10.38a | 00.10.38 | e862bc0b-0289-4661-bf0a-950e2efca6ee | Billing Requirements for Multiple Births for Professional Providers | Billing Requirements for Multiple Births for Professional Providers | {"3088": {"Id":3088,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5340,"PolicyAttachmentPageName":"ba5b6730-4f52-4c93-97c1-4ca8f4766879"},"3089": {"Id":3089,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5341,"PolicyAttachmentPageName":"494d41d3-1fd0-4df8-b729-ad76b6fc2723"},"3090": {"Id":3090,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5342,"PolicyAttachmentPageName":"1232f148-ec02-4366-a47a-8917edfa3d73"},"3091": {"Id":3091,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5343,"PolicyAttachmentPageName":"dee47969-1193-42f8-9cc1-4dabfcc50995"},} |
| | | 5671 | BiofeedbackTherapy07.00.01k | Medicine (07) | 07.00.01k | 07.00.01 | 9a1be15a-6a08-4a47-bb7e-fc09a9695011 | Biofeedback Therapy | Biofeedback Therapy | |
| | | 5632 | BioimpedencefortheDetectionofLymphedema07.06.03b | Medicine (07) | 07.06.03b | 07.06.03 | a832cdcc-2c89-40af-9e43-1102d942a08d | Bioimpedence for the Detection of Lymphedema | Bioimpedence for the Detection of Lymphedema | |
| | | 4845 | Blepharoplasty,RepairofBlepharoptosis,RepairofBrowPtosis,andCanthoplasty/Canthopexy11.05.02j | Surgery (11) | 11.05.02j | 11.05.02 | b491f109-dc4e-41fb-906a-5eb04fe2602d | Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy | Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy | {"4846": {"Id":4846,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6997,"PolicyAttachmentPageName":"665d1d9d-23ab-4d5d-9822-e83db0e70d80"},} |
| | | 5114 | Blinatumomab(Blincyto®)08.01.21f | Pharmacy (08) | 08.01.21f | 08.01.21 | b306af6e-813e-493c-8a8b-b57d5995a5e4 | Blinatumomab (Blincyto®) | Blinatumomab (Blincyto®) | |
| | | 5600 | Bone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06g | Surgery (11) | 11.01.06g | 11.01.06 | dcc2f693-5197-49ab-bec1-9281eb137d18 | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | |
| | | 5521 | BoneMineralDensity(BMD)Testing09.00.04n | Radiology (09) | 09.00.04n | 09.00.04 | 0dbfab1f-4412-4d17-9957-9d7dec231199 | Bone Mineral Density (BMD) Testing | Bone Mineral Density (BMD) Testing | |
| | | 5742 | Bortezomib(BortezomibforInjection,Velcade®)08.00.73p | Pharmacy (08) | 08.00.73p | 08.00.73 | 3e360ca0-6fe9-4af4-b906-30218d56a8f4 | Bortezomib (Bortezomib for Injection, Velcade®) | Bortezomib (Bortezomib for Injection, Velcade®) | {"5743": {"Id":5743,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7708,"PolicyAttachmentPageName":"62519bd9-92ee-47a8-8ddd-7fdade4cb835"},} |
| | | 5748 | BotulinumToxinAgents08.00.26ab | Pharmacy (08) | 08.00.26ab | 08.00.26 | d2645ebf-b782-4091-8c20-1c86b49c10ad | Botulinum Toxin Agents | Botulinum Toxin Agents | {"5749": {"Id":5749,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":7744,"PolicyAttachmentPageName":"17b60ed1-42bd-476f-95ea-84da05815fc1"},} |
| | | 4495 | BrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy09.00.10z | Radiology (09) | 09.00.10z | 09.00.10 | f581558f-daff-4a3d-8a3f-4a5256e1bf06 | Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy | Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy | |
| | | 5033 | BreastPumps05.00.76g | DME (05) | 05.00.76g | 05.00.76 | 7e4c86e0-e560-421c-8463-60b4239e18fa | Breast Pumps | Breast Pumps | |
| | | 4607 | BrentuximabVedotin(Adcetris®)08.01.13h | Pharmacy (08) | 08.01.13h | 08.01.13 | 2f4b8bc7-824b-4bd1-bffe-bc24075eb16a | Brentuximab Vedotin (Adcetris®) | Brentuximab Vedotin (Adcetris®) | {"4608": {"Id":4608,"MPAttachmentLetter":"A","Title":"ICD CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6762,"PolicyAttachmentPageName":"4ef59e2f-b124-4e39-bc83-d921fc98d944"},} |
| | | 5537 | BronchialValves11.16.09 | Surgery (11) | 11.16.09 | 11.16.09 | 2bab9fa4-c748-4063-85c4-82ade8f0220a | Bronchial Valves | Bronchial Valves | |
| | | 5360 | Burosumab-twza(Crysvita®)08.01.49b | Pharmacy (08) | 08.01.49b | 08.01.49 | 7086f118-eb42-44a3-8a89-e86e5c88d9cd | Burosumab-twza (Crysvita®) | Burosumab-twza (Crysvita®) | |
| | | 5367 | Canakinumab(Ilaris®)08.01.51b | Pharmacy (08) | 08.01.51b | 08.01.51 | 38c73bef-e52a-4cb7-a01c-656e866406c9 | Canakinumab (Ilaris®) | Canakinumab (Ilaris®) | |
| | | 5692 | CardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01p | Rehabilitation Services (10) | 10.01.01p | 10.01.01 | 094e8580-65c3-46fd-b661-804c2ab5e189 | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | {"5693": {"Id":5693,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7736,"PolicyAttachmentPageName":"ac655044-8cea-403c-b80e-7826290a05c8"},} |
| | | 5082 | CareManagementandCarePlanningServices00.01.59m | Administrative (00) | 00.01.59m | 00.01.59 | 1a75e5b2-239b-4d8f-ba0c-f6af7246660e | Care Management and Care Planning Services | Care Management and Care Planning Services | |
| | | 4813 | Carfilzomib(Kyprolis®)08.01.05i | Pharmacy (08) | 08.01.05i | 08.01.05 | 154ae50d-be6c-4132-ac0e-cd0daae0016c | Carfilzomib (Kyprolis®) | Carfilzomib (Kyprolis®) | |
| | | 4360 | CastandSplintApplicationsandAssociatedSupplies00.10.15d | Administrative (00) | 00.10.15d | 00.10.15 | 3d5103bb-27d5-4963-bd34-f6ba67f1076b | Cast and Splint Applications and Associated Supplies | Cast and Splint Applications and Associated Supplies | {"4361": {"Id":4361,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":6421,"PolicyAttachmentPageName":"4af8b16b-794b-4533-a048-5413712cbe65"},} |
| | | 4854 | CataractSurgery11.01.07f | Surgery (11) | 11.01.07f | 11.01.07 | 999dab46-d26f-4042-bdec-44679dace028 | Cataract Surgery | Cataract Surgery | {"4855": {"Id":4855,"MPAttachmentLetter":"A","Title":"ICD 10 codes for policy 11.01.07d, Cataract Surgery","MPPolicyAttachmentInternalSourceId":6668,"PolicyAttachmentPageName":"705428a5-5a31-40d0-a0d2-354e451b3896"},} |
| | | 5689 | CatheterAblationofCardiacArrhythmias11.02.06q | Surgery (11) | 11.02.06q | 11.02.06 | 9eccdc4b-79a3-4f95-8e04-651c93549127 | Catheter Ablation of Cardiac Arrhythmias | Catheter Ablation of Cardiac Arrhythmias | |
| | | 5565 | Cemiplimab-rwlc(Libtayo®)08.01.66c | Pharmacy (08) | 08.01.66c | 08.01.66 | b06a7d38-c9e9-4610-916b-190365fe9fd8 | Cemiplimab-rwlc (Libtayo®) | Cemiplimab-rwlc (Libtayo®) | |
| | | 5344 | Cerliponasealfa(Brineura®)08.01.39c | Pharmacy (08) | 08.01.39c | 08.01.39 | c81b22ec-3ec7-4a91-85c1-70af8b7cf771 | Cerliponase alfa (Brineura®) | Cerliponase alfa (Brineura®) | |
| | | 5183 | CervicalTractionDevicesforIn-homeUse05.00.61g | DME (05) | 05.00.61g | 05.00.61 | aff2b094-ca8b-410b-96e4-4a9c0c4fecbb | Cervical Traction Devices for In-home Use | Cervical Traction Devices for In-home Use | |
| | | 5019 | Cetuximab(Erbitux®)08.00.67n | Pharmacy (08) | 08.00.67n | 08.00.67 | 7a91e8d9-4bfe-4deb-978d-8f088449f615 | Cetuximab (Erbitux®) | Cetuximab (Erbitux®) | {"5020": {"Id":5020,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":7025,"PolicyAttachmentPageName":"9d4dd3a8-871d-43d3-8ff6-7f310fde867d"},"5021": {"Id":5021,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":7026,"PolicyAttachmentPageName":"aaa3078f-4999-485c-8564-30acef316ee7"},} |
| | | 4602 | ChemicalPeels11.08.08h | Surgery (11) | 11.08.08h | 11.08.08 | db5a3ccb-3f8a-411e-b545-f3ba973de1c5 | Chemical Peels | Chemical Peels | |
| | | 4605 | ChimericAntigenReceptor(CAR)Therapy08.01.43k | Pharmacy (08) | 08.01.43k | 08.01.43 | 828baa5b-e049-4764-b88b-528d65afed34 | Chimeric Antigen Receptor (CAR) Therapy | Chimeric Antigen Receptor (CAR) Therapy | {"4606": {"Id":4606,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6560,"PolicyAttachmentPageName":"c3da6cc6-10d3-42cd-afb6-fd746f9885a5"},} |
| | | 4819 | ChiropracticSpinalandExtraspinalManipulationTherapy10.02.02j | Rehabilitation Services (10) | 10.02.02j | 10.02.02 | 41b59432-3402-4af7-aced-f58e3d7ff391 | Chiropractic Spinal and Extraspinal Manipulation Therapy | Chiropractic Spinal and Extraspinal Manipulation Therapy | |
| | | 5495 | CoagulationFactors08.00.92af | Pharmacy (08) | 08.00.92af | 08.00.92 | d880288d-e445-4a8e-b601-541a53daee72 | Coagulation Factors | Coagulation Factors | |
| | | 5066 | Cobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54c | Pathology and Laboratory (06) | 06.02.54c | 06.02.54 | 359a2377-9b04-4dee-a8be-027bdc97c9b8 | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | {"5067": {"Id":5067,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":7156,"PolicyAttachmentPageName":"9555cfd8-5d27-439f-98b9-f8ac99996c49"},} |
| | | 5535 | CochlearImplantation11.01.02q | Surgery (11) | 11.01.02q | 11.01.02 | 4ee164ea-941e-469a-b9c0-41335b1bb8bd | Cochlear Implantation | Cochlear Implantation | |
| | | 5144 | Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo™)08.01.71 | Pharmacy (08) | 08.01.71 | 08.01.71 | 52fa70dc-94af-4f67-8cb5-471700f2dbd4 | Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™) | Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™) | |
| | | 5450 | ColorectalCancerScreening11.03.12t | Surgery (11) | 11.03.12t | 11.03.12 | 544ced3a-6c13-4171-8a56-94bd7fdaaa81 | Colorectal Cancer Screening | Colorectal Cancer Screening | |
| | | 4362 | ComplementaryandIntegrativeHealthServices12.00.03g | Miscellaneous (12) | 12.00.03g | 12.00.03 | 78256c85-c80a-49b2-a307-d5efd4b20b60 | Complementary and Integrative Health Services | Complementary and Integrative Health Services | |
| | | 5484 | CompleteDecongestiveTherapy(CDT)07.06.01b | Medicine (07) | 07.06.01b | 07.06.01 | cd8eb507-7b90-4fb0-9ad4-8a3d1338f17c | Complete Decongestive Therapy (CDT) | Complete Decongestive Therapy (CDT) | |
| | | 5093 | CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30 | Surgery (11) | 11.14.30 | 11.14.30 | 6c8a40e6-70ca-4754-af6a-14bd7b400f2a | Composite Tissue Allotransplantation of the Hand(s) and Face | Composite Tissue Allotransplantation of the Hand(s) and Face | |
| | | 5249 | CompressionGarments05.00.37g | DME (05) | 05.00.37g | 05.00.37 | 0b35e902-f311-4dd7-8f3b-a7219d7413c3 | Compression Garments | Compression Garments | |
| | | 5106 | Computer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42c | Radiology (09) | 09.00.42c | 09.00.42 | b9742429-a8a1-4644-8b1c-2d8a9c69cbbb | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | |
| | | 5076 | Computer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17e | Surgery (11) | 11.14.17e | 11.14.17 | 55481cd2-1b4b-4a4f-abf8-325c47863fc0 | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | |
| | | 5083 | ConsultationServices00.01.69b | Administrative (00) | 00.01.69b | 00.01.69 | fa3b31f7-c0c1-46d2-9619-2f49ae0825f7 | Consultation Services | Consultation Services | |
| | | 5140 | ContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11k | Medicine (07) | 07.13.11k | 07.13.11 | 59bf419b-18ab-4008-accf-9b541d9bdb26 | Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects | Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects | {"5141": {"Id":5141,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7217,"PolicyAttachmentPageName":"8be86c4f-061e-4c60-8520-fdeb5207de44"},} |
| | | 5138 | ContrastAgentsUsedinConjunctionwithEchocardiography09.00.11e | Radiology (09) | 09.00.11e | 09.00.11 | 12ca4dc2-6f5b-4375-a86a-975789fb3469 | Contrast Agents Used in Conjunction with Echocardiography | Contrast Agents Used in Conjunction with Echocardiography | |
| | | 5581 | CornealPachymetryUsingUltrasound07.13.07l | Medicine (07) | 07.13.07l | 07.13.07 | b3f30839-15d7-4589-9655-435e53e6412c | Corneal Pachymetry Using Ultrasound | Corneal Pachymetry Using Ultrasound | {"5582": {"Id":5582,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":7544,"PolicyAttachmentPageName":"ca7b96c8-3b6c-4c3e-8ef8-3ee9505c2b80"},} |
| | | 5538 | CoronaryArteryCalcium(CAC)TestingUsingComputedTomography(AmeriHealthAdministrators)09.00.58 | Radiology (09) | 09.00.58 | 09.00.58 | 77482876-6f27-4ea1-b0ec-3cc52520d7b6 | Coronary Artery Calcium (CAC) Testing Using Computed Tomography (AmeriHealth Administrators) | Coronary Artery Calcium (CAC) Testing Using Computed Tomography (AmeriHealth Administrators) | |
| | | 5390 | CosmeticProcedures12.01.03b | Miscellaneous (12) | 12.01.03b | 12.01.03 | ce92180b-3b91-4668-af51-0aa525646307 | Cosmetic Procedures | Cosmetic Procedures | |
| | | 5737 | CoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08n | Pharmacy (08) | 08.01.08n | 08.01.08 | f7ae692a-ba80-454f-ba92-3c7635a5dbcf | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | {} |
| | | 3720 | CoverageofMedicalDevices05.00.04e | DME (05) | 05.00.04e | 05.00.04 | 14669bc5-097a-4a2c-bbf0-82a2e0da5a62 | Coverage of Medical Devices | Coverage of Medical Devices | |
| | | 5601 | CranialElectrotherapyStimulation05.00.80c | DME (05) | 05.00.80c | 05.00.80 | da959899-1ad2-4f8a-baf2-baa16d2f1d26 | Cranial Electrotherapy Stimulation | Cranial Electrotherapy Stimulation | |
| | | 5681 | CranialRemoldingOrthoses(Helmets)05.00.25j | DME (05) | 05.00.25j | 05.00.25 | 0d9aa219-e1dd-4046-88e4-f538aed7afe8 | Cranial Remolding Orthoses (Helmets) | Cranial Remolding Orthoses (Helmets) | |
| | | 5034 | CriteriaforReimbursementofEmergencyRoomServices00.10.03k | Administrative (00) | 00.10.03k | 00.10.03 | cde76797-199e-4918-9e43-897124bfa2c4 | Criteria for Reimbursement of Emergency Room Services | Criteria for Reimbursement of Emergency Room Services | |
| | | 5727 | crizanlizumab-tmca(Adakveo®)08.00.04a | Pharmacy (08) | 08.00.04a | 08.00.04 | 177478c4-a9ce-4845-b972-98a5a3cf3df6 | crizanlizumab-tmca (Adakveo®) | crizanlizumab-tmca (Adakveo®) | |
| | | 4370 | CryosurgicalAblationoftheProstateGland11.11.03d | Surgery (11) | 11.11.03d | 11.11.03 | f1cff10d-b7bc-40e7-b5db-a6fe5f3bf3f2 | Cryosurgical Ablation of the Prostate Gland | Cryosurgical Ablation of the Prostate Gland | |
| | | 4558 | Daratumumab(Darzalex®),Daratumumab,andHyaluronidase-fihj(DarzalexFaspro®)08.01.29j | Pharmacy (08) | 08.01.29j | 08.01.29 | bac83114-7a60-4245-84f3-bd19dc5948d3 | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | |
| | | 5378 | DayRehabilitation10.00.02c | Rehabilitation Services (10) | 10.00.02c | 10.00.02 | 803d7702-4e64-481a-a856-89a699b735d9 | Day Rehabilitation | Day Rehabilitation | |
| | | 5125 | DebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNails11.08.17k | Surgery (11) | 11.08.17k | 11.08.17 | d42f70a6-a972-422f-9fc4-142aa04bdff1 | Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails | Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails | {"5126": {"Id":5126,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":7200,"PolicyAttachmentPageName":"56d13ffe-d9ac-4d35-ab1d-18449a04914d"},"5127": {"Id":5127,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":7201,"PolicyAttachmentPageName":"f0919ea2-26c8-4fde-8f96-fb6302d2c684"},"5128": {"Id":5128,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":7202,"PolicyAttachmentPageName":"1e791c22-0b98-449d-9e3a-71ca1ac1b1a6"},"5129": {"Id":5129,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":7203,"PolicyAttachmentPageName":"6d4c7c59-658d-475a-8e9c-eb7c4300c94b"},"5130": {"Id":5130,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":7204,"PolicyAttachmentPageName":"d0339e3b-5a2e-4ff9-ac14-fe15ec87bc41"},} |
| | | 5718 | DeepBrainStimulation(DBS)11.15.20s | Surgery (11) | 11.15.20s | 11.15.20 | 42481246-b90c-4838-ad70-3c7e4d01879d | Deep Brain Stimulation (DBS) | Deep Brain Stimulation (DBS) | |
| | | 5240 | DenervationoftheSpinalNervesforChronicPain(AmerihealthAdministrators)11.15.09p | Surgery (11) | 11.15.09p | 11.15.09 | 7ad193a1-4356-4c00-8be7-6d555ca8dcee | Denervation of the Spinal Nerves for Chronic Pain (Amerihealth Administrators) | Denervation of the Spinal Nerves for Chronic Pain (Amerihealth Administrators) | |
| | | 5746 | Denosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)08.00.94q | Pharmacy (08) | 08.00.94q | 08.00.94 | 57bda5d7-15fe-46b5-a899-86ca6605e4b3 | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | {"5747": {"Id":5747,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":7711,"PolicyAttachmentPageName":"3f4108f4-df79-4a2b-8350-997ae2afe344"},} |
| | | 5643 | DermabrasionforRhinophyma,Septoplasty,Rhinoplasty,andSeptorhinoplasty11.16.01k | Surgery (11) | 11.16.01k | 11.16.01 | eb0d2a2d-0772-49af-aa74-3b8d38e08143 | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | |
| | | 5005 | DiagnosticRadiologyServicesIncludedinCapitation00.03.02ad | Administrative (00) | 00.03.02ad | 00.03.02 | 34cffd2e-5f5c-447d-95c6-4f2546aea666 | Diagnostic Radiology Services Included in Capitation | Diagnostic Radiology Services Included in Capitation | {"5006": {"Id":5006,"MPAttachmentLetter":"A","Title":"Diagnostic Radiology Procedure Codes Included in Capitation for Pennsylvania (PA) Health Maintenance Organization (HMO) Members","MPPolicyAttachmentInternalSourceId":7126,"PolicyAttachmentPageName":"41cccf03-47bb-4b9f-85ec-a3da4e01e20e"},} |
